What is ARCT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.39B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ARCT?

P/E (TTM) is n/a and 52-week range is $5.50 to $24.17 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ARCT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ARCT?

The company profile lists revenue (TTM) near $29M, net income (TTM) near $-9.33B, EPS (TTM) near $-3.31 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Arcturus Therapeutics Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 28.4M shares outstanding, ISIN US03969T1097 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Arcturus Therapeutics Holdings Inc

$ARCT

Health Care · Biotechnology

IR Run Scenarios

$13.74

+6.76%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 106 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Employees

106

Website

arcturusrx.com/

IPO

2013-05-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)